Citigroup’s Icosavax ICVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-440,892
| Closed | -$6.95M | – | 5934 |
|
|
2023
Q4 | $6.95M | Buy |
440,892
+126,390
| +40% | +$1.22M | ﹤0.01% | 1398 |
|
|
2023
Q3 | $2.44M | Sell |
314,502
-7,938
| -2% | -$65.8K | ﹤0.01% | 1865 |
|
|
2023
Q2 | $3.2M | Buy |
322,440
+8,201
| +3% | +$65.6K | ﹤0.01% | 1807 |
|
|
2023
Q1 | $1.82M | Sell |
314,239
-185
| -0.1% | -$1.6K | ﹤0.01% | 2086 |
|
|
2022
Q4 | $2.5M | Sell |
314,424
-5,183
| -2% | -$22.2K | ﹤0.01% | 1873 |
|
|
2022
Q3 | $1.01M | Buy |
319,607
+225,276
| +239% | +$1.41M | ﹤0.01% | 2704 |
|
|
2022
Q2 | $541K | Buy |
94,331
+80,328
| +574% | +$627K | ﹤0.01% | 3164 |
|
|
2022
Q1 | $99K | Buy |
14,003
+9,182
| +190% | +$144K | ﹤0.01% | 4420 |
|
|
2021
Q4 | $110K | Buy |
4,821
+3,286
| +214% | +$84.9K | ﹤0.01% | 4685 |
|
|
2021
Q3 | $45K | Buy |
+1,535
| New | +$52K | ﹤0.01% | 4798 |
|
Citigroup's ICVX Position: Q1 2024 in Review
Citigroup sold out of Icosavax (ICVX) in Q1 2024, closing a stake of 440,892 shares — an estimated $6.95M sold.
Citigroup first reported a position in ICVX in Q3 2021 and held it in 10 quarters. The position peaked at $6.95M in Q4 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.
- Citigroup reported no remaining Icosavax position as of Q1 2024 after selling out during the quarter.
- Citigroup sold 440,892 Icosavax shares in Q1 2024, an estimated $6.95M.
- Citigroup first reported a position in Icosavax in Q3 2021 and held it in 10 quarters.
- Citigroup's Icosavax position peaked at $6.95M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Icosavax as of Q1 2024.
Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.